Stratrix
On the Record · Cencora

Cencora acquisitions, on the record

The businesses Cencora bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
PharmaLex Holding GmbH
Word for word“In September 2022, we entered into a definitive agreement to acquire PharmaLex Holding GmbH (“PharmaLex”), a leading provider of specialized services for the life sciences industry, for €1.28 billion in cash, subject to customary adjustments.” 10-K for 2022
agreed acquisitionSeptember 2022€1.28 billion in cash
Alliance Healthcare
Word for word“On June 1, 2021, we completed our acquisition of Alliance Healthcare from WBA for $5,596.7 million in net cash, $229.1 million of the our common stock, and $6.1 million of other equity consideration (see Note 2 of the Notes to Consolidated Financial Statements).” 10-K for 2022
acquisitionOn June 1, 2021$5,596.7 million in net cash
non-core subsidiaries
Word for word“We completed the sales of non-core subsidiaries in the fiscal year ended September 30, 2022 and received total proceeds $272.6 million, subject to final working capital adjustments.” 10-K for 2022
divestiturefiscal year ended September 30, 2022total proceeds $272.6 million
Profarma Specialty
Word for word“International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).” 10-K for 2022
divestitureJune 2022—
Brazil specialty business
Word for word“Revenue in International Healthcare Solutions increased by $0.9 billion, or 3.5%, from the prior fiscal year due to increased sales at Alliance Healthcare, our European distribution business, increased revenue from our less-than-wholly-owned Brazil full-line distribution business, incremental revenue from our January 2023 acquisition of PharmaLex, and increased sales at our Canadian business.” 10-K for 2023
divestiture——
less-than-wholly-owned subsidiary in Egypt
Word for word“Operating income in International Healthcare Solutions decreased by $13.9 million, or 2.0%, from the prior fiscal year due to a decrease in operating income in our European distribution business primarily due to unfavorable foreign currency exchange rates in comparison to the prior fiscal year and a significant decline in operating income at its less-than-wholly-owned subsidiary in Egypt (that was divested on September 30, 2023), and the June 2022 divestiture of our Brazil specialty business.” 10-K for 2023
divestitureSeptember 30, 2023—
Retina Consultants of America
Word for word“On November 5, 2024, we entered into an agreement to acquire Retina Consultants of America ("RCA").” 10-K for 2024
agreed acquisitionNovember 5, 2024—
OneOncology, LLC
Word for word“In June 2023, the Company and TPG, a global alternative asset management firm, acquired OneOncology, LLC ("OneOncology"), a network of leading oncology practices.” 10-K for 2024
acquisitionJune 2023—
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Cash received from selling businessesGoodwill from acquisitions
2016-09-30$2.73 billion$0$1.85 billion
2017-09-30$61.6 million$12.1 million$54.2 million
2018-09-30$785.3 million$0$681.3 million
2019-09-30$64 million$0$43.4 million
2020-09-30$0$0—
2021-09-30$5.56 billion$0$2.49 billion
2022-09-30$133.8 million$272.6 million$26.1 million
2023-09-30$1.41 billion$0$1.03 billion
2024-09-30$69.8 million$0$18.7 million
2025-09-30$4.1 billion—$5.02 billion

Deal filings since 2016

Read from Cencora’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2025-11-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.